Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease

Amicus Therapeutics Inc FOLD has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease.

  • Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability, or increases in forced vital capacity (FVC).
  • The data also exhibited persistent and durable reductions in key biomarkers of muscle damage and disease substrate across all patient cohorts.
  • AT-GAA is currently under global regulatory reviews. 
  • Also Read: Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall.
  • The FDA accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA, with action dates of July 29 and May 29
  • Long-term data from the Phase 3 PROPEL open-label extension study is expected to be presented later this year.
  • To date, adverse events have been generally mild and transient.
  • Price Action: FOLD shares are up 2.46% at $9.17 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!